JS002

· Shanghai Junshi Bioscience Co., Ltd.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for JS002, covering 2020-07-14 to 2024-09-19. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia [Phase 3]

See pricing